S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Checked against the public recordLast updated Oct 26, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- SWOG Cancer Research Network
- Interventions being studied
- Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * Stage I, II, IIIA, or IIIB (T4 or N3) disease * No malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met: * Benign pleural fluid * Pleural fluid is due to prior thoracotomy * Pleural fluid is deemed too small to safely tap * No diagnosis by cytology alone * Newly diagnosed disease * Must have tumor blocks/slides available and must be willing to provide tissue samples * Prior smoking history meeting 1 of the following criteria: * Never smoker, defined as \< 100 cigarettes in lifetime * Former smoker, defined as no smoking for ≥ 1 year * Current smoker, defined as all others (closed to accrual as of 7/15/07) * No pericardial effusions PATIENT CHARACTERISTICS: * No other prior malignancy except for 1 of the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Other cancer for which the patient has been disease free for five years PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy * Concurrent participation in therapeutic trials allowed
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Providence Cancer CenterAnchorage, Alaska
- Arizona Cancer Center at University of Arizona Health Sciences CenterTucson, Arizona
- Hembree Mercy Cancer Center at St. Edward Mercy Medical CenterFort Smith, Arkansas
- Kaiser Permanente - Deer ValleyAntioch, California
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical CenterBurbank, California
- Cancer Care Center at John Muir Health - Concord CampusConcord, California
- North Bay Cancer CenterFairfield, California
- Kaiser Permanente - FremontFremont, California
- Glendale Memorial Hospital Comprehensive Cancer CenterGlendale, California
- Kaiser Permanente Medical Center - HaywardHayward, California
- Tibotec Therapeutics - Division of Ortho Biotech Products, LPMarysville, California
- Kaiser Permanente Medical Center - OaklandOakland, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 26, 2015. Always confirm current availability with the study team.